Loading...
•
Dec 31, 2020
Relmada Q4 2020 Earnings Report
Relmada Therapeutics reported financial results and provided a corporate update.
Key Takeaways
Relmada Therapeutics reported their Q4 and full-year 2020 financial results, highlighting the initiation of their Phase 3 program for REL-1017 and anticipating multiple data readouts over the next several quarters. The company also reported a strong balance sheet to drive development efforts.
Phase 3 program for REL-1017 as adjunctive treatment for major depressive disorder was initiated.
Multiple data readouts are anticipated over the next several quarters.
The company has a strong balance sheet driving development efforts.
First of two Phase 3 trials, RELIANCE I, is enrolling as planned, and RELIANCE II is expected to begin imminently.
Forward Guidance
Relmada Therapeutics anticipates multiple key data readouts over the next several quarters, including data from the oxycodone human abuse potential study in Q2 2021, followed by data from the IV ketamine human abuse potential study by year-end 2021. Top-line data from both RELIANCE I and RELIANCE II is expected in the first half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...